// App-Quantinova.ai

DMT05 : Effectiveness, Safety and PROs of Ofatumumab in RMS Patients Switching from Dimethyl Fumarate or Fingolimod: Artios Phase 3b Study Design

Researchers

Presenter

  • Matthew Craner

Principal Investigators

  • Riley Bove

  • Dawn Langdon

  • Daniel Detka

  • Javier Ricart

  • Alomi Mistry

  • Patricia Maxwell

  • Chaitali Babanra Pisal

  • Pruthvi Desireddy

  • Dee Stoneman

  • Marina Ziehn

  • Tobias Derfuss

Medical Centers

  • Royal Holloway, University of London, London, UNITED KINGDOM

  • Neurologic Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland

  • Novartis AG, Basel, Switzerland

  • University of California, San Francisco, San Francisco, CA

  • John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, UNITED KINGDOM

  • 1Novartis Farmacéutica S.A. Barcelona Spain

Locations

  • United Kingdom

  • India

  • United States

  • Switzerland

  • Spain

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Genetic Disorder

  • Dermatology

  • Central Nervous System (CNS)

Disease

  • Depression

  • Anxiety

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • Glial fibrillary acidic protein

  • Neurofilament-light chain

Drug/Treatment

  • Dimethyl fumarate

  • Fingolimod

  • ofatumumab Intravenous

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

  • Prospective

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved